Nigel P. Mongan

University of Nottingham — United Kingdom

Biochemistry, Genetics and Molecular Biology · Life Sciences

47h-index8.5kcitations260works2.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer Genomics and Diagnostics(35), Prostate Cancer Treatment and Research(33), Epigenetics and DNA Methylation(30), Cancer Cells and Metastasis(25), Breast Cancer Treatment Studies(22)

Publications260 total

Clinicopathological and functional evaluation of replication protein A in epithelial ovarian cancers: A target validation study
Translational Oncology·2026Open Access
Loss of piR-hsa-7221 regulation drives the expression of the LINE1-derived oncogenic lncRNA CASC9 in testicular cancer
2026Open Access
Detecting Mitochondrial Free Radicals with Quantum Sensors: From Organelles to a <i>D. melanogaster</i> Model of Neurodegeneration
2025Open Access
Functional and clinical significance of the RNA m6A methyltransferase complex in breast cancer
npj Breast Cancer·2025Open Access
Clinicopathological Significance of Transcription Factor p73 in Breast Cancers: Protein Expression and Transcriptomic Study
Biomedicines·2025Open Access
Outcome prediction of oestrogen receptor‐positive breast cancer based on a panel of oestrogen receptor‐regulated genes
Histopathology·2025Open Access
The functional and therapeutic potential of epitranscriptomics in breast cancer
Epigenomics·2025Open Access
Investigation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal potential therapeutic opportunities
Scientific Reports·2025· 3 citedOpen Access
Erratum to “Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay” [Modern Pathology 38 (2025) 100713]
Modern Pathology·2025Open Access
Epigenetic Therapies in Endocrine-Related Cancers: Past Insights and Clinical Progress
Cancers·2025· 2 citedOpen Access
Evaluation of human papillomavirus as a risk factor in prostate cancer pathogenesis
Discover Oncology·2025Open Access
Abstract P3-02-23: Evaluation of ribociclib, abemaciclib and palbociclib resistance in ER+ breast cancer cells reveal novel therapeutic opportunities in ER+/HER2- breast cancers
Clinical Cancer Research·2025
Comparison of Differentially Expressed Genes in Human and Canine Osteosarcoma
Life·2025· 2 citedOpen Access
Abstract 2911: Unravelling the role of AP-1 transcription factor in DNA damage signaling and response (DDR), platinum and PARP inhibitor resistance in ovarian cancers
Cancer Research·2025
Characterisation of <scp>HER</scp>2‐Driven Morphometric Signature in Breast Cancer and Prediction of Risk of Recurrence
Cancer Medicine·2025Open Access
Transcription Factor p73 Is a Predictor of Platinum Resistance and Promotes Aggressive Epithelial Ovarian Cancers
International Journal of Molecular Sciences·2025Open Access
Cardiotoxicity of breast cancer drug treatments
Translational Oncology·2025· 5 citedOpen Access
P026: Prediction of response to anti-HER2 therapy using multigene assay
The Breast·2025Open Access
Prediction of Response to Anti-HER2 Therapy Using A Multigene Assay
Modern Pathology·2025Open Access
Insulin-like Growth Factor 1 (IGF1) and Its Isoforms: Insights into the Mechanisms of Endometrial Cancer
Cancers·2025· 4 citedOpen Access
page 1 of 13Next →

Frequent Co-authors

Lorraine J. Gudas(16), Jenny L. Persson(10), Emad A. Rakha(8), Niels Ødum(7), Ian O. Ellis(7), Andrew R. Green(7), Stephen A. Boorjian(5), Thorbjørn Krejsgaard(4), Lise M. Lindahl(4), Mariusz A. Wasik(4), Ivan V. Litvinov(4), Lars Iversen(4), Anders Woetmann(4), Chitra Joseph(4), Mansour Alsaleem(4), Cinzia Allegrucci(4), Mohammed A. Aleskandarany(4), David M. Heery(4), Zsuzsanna Bódi(3), Nathan Archer(3)